Form 8-K · Current Report · Filed 2026-01-13
Cardinal Health Raises Fiscal 2026 Outlook
Cardinal Health, Inc. has raised its fiscal year 2026 non-GAAP diluted earnings per share (EPS) outlook to at least $10.00, up from its prior guidance range of $9.65 to $9.85. The company anticipates Specialty revenues surpassing $50 billion, representing a 16% compounded annual growth rate over three years. Additionally, Cardinal Health successfully transitioned its manufacturer distribution service agreements for all branded pharmaceutical products impacted by the 2026 Medicare Drug Price Negotiation Program. The company also introduced the ContinuCare Pathway program to simplify diabetes supply management for partner pharmacies and patients, announcing a key partnership with Publix Super Markets Inc.
- Filer
- Cardinal Health Inc. CAH · NYSE
- Filed
- Accession
- 0000721371-26-000003
- CIK
- 0000721371
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$202.52
Next session
+5.5%
Since filing
+13.6%
Latest close
$230.03
What happened, not what will happen — closing prices around the filing date.
About Cardinal Health Inc.
Cardinal Health Inc. is a major global healthcare services and products company, distinguished for providing end-to-end medical solutions. Specializing in healthcare distribution and supply chain management, Cardinal Health serves a comprehensive array of clients including hospitals, pharmacies, and healthcare providers. Notably, the company distributes pharmaceuticals, medical products, and laboratory supplies, ensuring efficient delivery to improve healthcare outcomes. Based in Dublin, Ohio, Cardinal Health plays a pivotal role in enhancing healthcare operational efficiency, offering extensive services like inventory management, logistics optimization, and integrated healthcare solutions that empower providers to focus on patient care. As one of the largest pharmaceutical distributors in the United States, it holds substantial influence in the healthcare sector, pivotal in ensuring the availability of drugs and medical supplies across various platforms, contributing significantly to the healthcare infrastructure worldwide.
Never miss another CAH filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.